Search Results

ModeX Therapeutics Inc., an OPKO Health company, announced results from a Phase 1 clinical study of SAR441236, its trispecific broadly neutralizing antibody against the human immunodeficiency virus, at the 2024 Conference on Retroviruses and Opportunistic Infections in Denver, Colorado.

Nona Biosciences today announced it has entered into an agreement with ModeX Therapeutics, an OPKO Health company, for the use of Nona’s platforms to support ModeX’s development of multispecific antibody therapeutics.

ModeX Therapeutics Inc., an OPKO Health, Inc. company, has been awarded a contract from the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services, to advance a platform and specific candidates designed to address a range of public health threats in viral infectious diseases.

OPKO Health, Inc. announced that ModeX Therapeutics, Inc., an OPKO Health company, entered into an exclusive worldwide license and collaboration agreement with Merck, known as MSD outside the United States and Canada, for the development of MDX-2201, ModeX’s preclinical nanoparticle vaccine candidate targeting EBV.

Shionogi & Co., Ltd. and Maze Therapeutics, Inc. announced the companies have completed an exclusive worldwide license agreement for the rights to MZE001, an investigational oral glycogen synthase 1 inhibitor that aims to address Pompe disease by limiting disease-causing glycogen buildup.